Administration of exogenous GM-CSF is known to inhibit several models of autoimmunity, including experimental autoimmune myasthenia gravis, experimental autoimmune thyroiditis, and type I diabetes via the induction of “tolerogenic DC” and regulatory T cell subsets (43, 46–56, 82–91). Here, CSF2 is linked to myasthenia gravis.